top of page
lab-7.png

Contract Research
Partner

​We are more than a traditional CRO (Contract Research Organization).

We are a Contract Research Partner.

Fragment-Based Lead Discovery at NMX

Our comprehensive approach to biophysical methodology, along with our proprietary, expertly curated fragment libraries for FBLD screens, enables us to support your hit-to-lead project at every phase.

Biophysics Platform

Innovative workflows with orthogonal methods allow us to fully assess ligand-compound binding kinetics, compound behaviour, protein stability, target binding sites/pockets, and more.

Biophysics Platform

Innovative NMR protocols specifically designed to optimize the screening, binding and characterization processes.

Molecule background

NMX Empowers Drug Discovery with Advanced Fragment Screening Solutions 

Our High-throughput biophysical screening platform utilizes our proprietary fragment librairies

About us

NMX Research & Solutions Inc. is a pionneering contract research organization (CRO) specializing in Fragment-Based Drug Discovery (FBDD) and biophysical screening technologies.

​

Founded in 2014, NMX is dedicated to accelerating drug discovery by providing innovative solutions and state-of-the-art services to the biotechnology and pharmaceutical industries.

Our mission

Delivering high-quality actionable insights

To drive the discovery and development of new drugs by leveraging our expertise in biophysics, medicinal chemistry and structural biology.

Our Expertise

Decades of experience in various fields

  • Fragment-Based Lead Discovery (FBLD)

  • Biophysical Screening 

  • Medicinal Chemistry

  • Protein Production

Depositphotos_174991348_L.jpg

Accelerate Your Path to Discovery

bottom of page